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Abstract
Background—Influenza viruses gradually accumulate point mutations, reducing the 
effectiveness of prior immune protection.
Methods—Children aged 9–14 years received 2010–2011 trivalent inactivated influenza vaccine 
(TIV). Vaccination history, hemagglutination-inhibition (HI) titers, and cell-mediated immune 
responses were assessed to investigate the cross-reactivity with past and future influenza virus 
strains.
Results—2010–2011 TIV induced significant T-cell responses and HI titers of ≥160, with a fold-
rise of ≥4 and titers of ≥100 maintained for >7 months in the majority of children. Pre-existing 
memory B cells in these children differentiated quickly to antibody-secreting cells to the new 
vaccine antigens. Children vaccinated in the previous year maintained high HI titers well into 
2010, demonstrating elevated HI titers against A/Perth/16/2009, the future (in 2010–2011) H3N2 
component. Prior vaccination enhanced CD8+ T-cell responses to A/Perth/16/2009. Children 
vaccinated with the prior 2009–2010 seasonal vaccine also demonstrated higher preexisting levels 
of interferon γ–secreting CD4+CD69+ T cells to 2009 pandemic influenza A(H1N1). Children 
previously vaccinated with 2009–2010 seasonal influenza vaccine also showed greater expansion 
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of tumor necrosis factor α–secreting CD8+CD69+ T cells to 2009 pandemic influenza A(H1N1) 
upon vaccination in the 2010–2011 season than those who were not previously vaccinated.
Conclusions—Seasonal influenza viruses continuously drift, which allows them to circumvent 
protective immunity, but conserved epitopes provide immunological cross-reactivity in children 
through either vaccination directly or through prime/boost in the prior influenza season.
Keywords
B cell; children; cross-reactivity; hemagglutination inhibition; immune response; influenza; T cell; 
vaccine
Influenza viruses continuously evolve through antigenic drift and shift. On rare occasions, 
unique strains arise when an influenza strain acquires genetic segments from another strain. 
These antigenically shifted strains are serologically distinct with no cross-protection in the 
human population, resulting in influenza pandemics approximately once every 36 years [1]. 
More commonly, influenza viruses evolve gradually, accumulating point mutations in 
hemagglutinin (HA) antibody-binding sites, enhancing their ability to escape preexisting 
immunity and reinfect previously protected individuals [2].This antigenic drift prompts a 
yearly race to accurately predict next season’s circulating strains and manufacture a 
sufficient quantity of vaccine prior to the influenza season. This occasionally results in 
mismatch between vaccines and circulating strains that have significantly drifted early in the 
influenza season, as occurred during the 2014–2015 influenza season [3]. Despite 
continuous drift, emerging strains maintain some degree of antigenic similarity with their 
immediate predecessors [4, 5], and vaccines usually provide at least partial protection to 
drifted strains [3, 6, 7].
Annual influenza epidemics exert effects worldwide; however, children are 
disproportionately affected. The US Advisory Committee on Immunization Practices 
recommends that all children aged 6 months to 18 years receive influenza vaccine annually 
[8]. Nevertheless, it is estimated only half of American children are vaccinated yearly [9]. 
Despite waning immunity throughout the year, children vaccinated in the prior influenza 
season likely receive some additional benefit in subsequent seasons due to retained antigenic 
similarity. We examined immune responses in children vaccinated with trivalent inactivated 
influenza vaccine (TIV), assessing parameters likely to play a role in protection, including 
development of hemagglutination-inhibition (HI) titers, T-cell and B-cell responses, and 
influences of prior vaccination.
METHODS
Methods are summarized briefly here and in detail in Supplementary Figure 1.
Study Design
Fifty children aged 9–14 years (Table 1) were vaccinated on 9–16 October 2010 with 
unadjuvanted 2010–2011 TIV composed of A/California/07/09 (2009 pandemic influenza 
A[H1N1]; hereafter, A[H1N1]pdm09), A/Perth/16/2009(H3N2) (hereafter, A/Perth/16), and 
B/Brisbane/60/2008 (hereafter, B/Bris/60) strains. Serum was collected at 0 days, 28 days, 
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and 7 months after vaccination, and peripheral blood mononuclear cells (PBMCs) were 
collected on day 0 from all subjects and at only 1 time point after vaccination, either 7 days, 
14 days, or 28 days, because of the subjects’ age. One child was unavailable for the 7-month 
serum collection. Informed consent was obtained from subjects, and human experimentation 
guidelines of the Department of Health and Human Services were followed. Procedures, 
informed consent documents, and data collection forms were approved by participating 
institutional review boards.
Serological Assays
HI assays were performed by Focus Diagnostics (Cypress, California) as previously 
described [10]. HI titers were determined against the 2010–2011 vaccine strains 
A(H1N1)pdm09, A/Wisconsin/15/2009(H3N2) (an A/Perth/16-like strain), and B/Bris/60; 
the 2009–2010 vaccine strains A/Brisbane/59/2007(H1N1) (hereafter, A/Bris/59) and A/
Uruguay/716/2007(H3N2) (an A/Brisbane/10/2007-like strain; A/Bris/10); and the 2008–
2009 influenza B vaccine strain, B/Florida/4/2006 (B/Flor/4).
T-Cell Responses
PBMCs were stimulated overnight with live A(H1N1)pdm09 (A/California/08/09) or A/
Perth/16 as previously described [11] or with recombinant HA (rHA; Influenza Reagent 
Resource, Manassas, VA). PBMCs were stained with Live/Dead Stain (Life Technologies, 
Grand Island, New York) and then stained for surface CD56, CD69, CD4, and CD8 and 
intracellular tumor necrosis factor α (TNF-α), interleukin 2, and interferon γ (IFN-γ). T-
cell activation determined within the CD56− population was expressed as CD4+CD69+ or 
CD8+CD69+ cells in total CD4+ or CD8+ T cells. Cytokine-producing cells were expressed 
within total CD4+CD69+ or CD8+CD69+ cells.
Antibody-Secreting Cells (ASCs)
Antigen (Ag)–specific memory B cells were assessed in PBMCs collected 28 days after 
vaccination, and plasmablasts were derived from preexisting memory B cells assessed in 
samples obtained 7 days after vaccination. PBMCs stimulated to induce polyclonal 
activation (Supplementary Figure 1) were added to enzyme-linked immunospot (ELISPOT) 
plates coated with anti-human immunoglobulin G (IgG), immunoglobulin M (IgM; Southern 
Biotech, Birmingham, Alabama), or monovalent influenza vaccines (kindly provided by 
Sanofi Pasteur, Swiftwater, Pennsylvania). Spot-forming units were assessed by 
ImmunoSpot ELISPOT reader (Cellular Technology, Cleve-land, Ohio) and expressed as the 
percentage of Ag-specific IgG-or IgM-secreting B cells out of the total number of IgG- or 
IgM-secreting B cells.
Statistical Analysis
Log2-transformed HI titers were used as dependent variables, summarized as geometric 
mean titers (GMTs). Means and differences in means were estimated using repeated 
measures linear mixed models as previously reported [11]. Model-estimated means yielded 
GMTs and differences between GMTs (28 days and 0 days, 7 months and 0 days, and 7 
months and 28 days) yielded GMT ratios (fold rise). B-cell responses were analyzed as 
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previously reported [11]; percentages were log10 transformed and summarized as geometric 
mean percentages (GMPs) and GMP ratios. T-cell analyses used a generalized linear mixed 
model with binomial error distribution to directly estimate the percentage of responding 
cells. Final results were back-transformed to a linear scale. Analyses were performed using 
SAS software (SAS Institute, Cary, North Carolina). Children grouped by prior vaccination 
(both seasonal and monovalent A[H1N1]pdm09 vaccines) were assessed for effects of prior 
vaccination on 2010–2011 TIV responses. For this analysis, post-vaccination T-cell 
responses (on days 7, 14, and 28) were grouped and differences in cellular responses and HI 
titers determined using unpaired t tests. The Fisher exact test was used to compare the 
proportions of children reaching HI titers of ≥40, 80, and 160.
RESULTS
Serological Responses
Children had increased HI titers to all 2010–2011 TIV strains (Figure 1), with the majority 
achieving a fold-rise of ≥4 (Table 2). Titers declined over 7 months but remained well above 
prevaccination levels (Figure 1). Vaccination also induced a fold-rise of ≥4 to the previous 
year’s A(H3N2) strain in 68% of children (Table 2).
HI titers of ≥32 or ≥40 are considered to reduce risk of influenza virus infection by 50% in 
young, healthy adults [12, 13]; however, recent studies conflict as to what level is applicable 
to children. Studies by Ng et al confirmed the use of 40 [14], while Black et al suggest that a 
50% reduction is associated with HI titers of >100 [15]. We therefore examined HI titers of 
≥40, 80, and 160 (Table 2). Before vaccination, 58% of children had HI titers of <40 to A/
Bris/59, the previous year’s A(H1N1) component (Table 2). In contrast, 68% exhibited 
preexisting HI titers of ≥40 to A(H1N1)pdm09, potentially through prior natural infection. 
2010–2011 TIV increased A(H1N1)pdm09 titers, with >95% achieving HI titers of ≥40 and 
titers remaining >40 beyond 7 months; 86% achieved titers of ≥160, with titers in 67.3% 
remaining >160 for 7 months (Table 2).
Prior to vaccination in 2010, 64% of children had HI titers of ≥40 to A/Bris/10, the 2009–
2010 A(H3N2) vaccine component, and 30% had preexisting titers of ≥40 to A/Perth/16, the 
2010–2011 A(H3N2) component (Table 2). 2010–2011 TIV induced HI titers to both 
strains; 66% and 84% achieved HI titers of ≥160 to A/Perth/16 and A/Bris/10, respectively, 
and maintained these elevated levels beyond 7 months.
The 2010–2011 TIV B component, B/Bris/60, was retained from the previous year. Half of 
subjects had preexisting HI titers of ≥40 and similar titers to B/Flor/4, the B strain from 2 
years prior (Table 2 and Figure 1). 2010–2011 TIV increased HI titers to both strains (Table 
2).
T-Cell Responses
Increased percentages of activated (CD69+) T cells were detectable at most time points after 
vaccination without in vitro stimulation but were not statistically significant with the 
exception of IFN-γ–secreting CD4+CD69+ cells 7 days after vaccination (Supplementary 
Figure 2; P ≤ .05). Activated CD4+ T cells (CD4+CD69+) responded to live-virus 
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stimulation primarily with IFN-γ production, while activated CD8+ T cells (CD8+CD69+) 
responded primarily with TNF-α secretion. Increased IFN-γ–secreting CD4+CD69+ cells 
were observed 14 days after vaccination after live A(H1N1)pdm09 stimulation (P ≤ .05) and 
14 days (P ≤ .05) and 28 days (P ≤ .01) after vaccination against live A/Perth/16 (Figure 2). 
A/Perth/16 also stimulated TNF-α production 14 days after vaccination (P ≤ .05). Increased 
TNF-α–secreting CD8+CD69+ cells were observed 14 days (P ≤ .01) and 28 days (P ≤ .01) 
after vaccination to A(H1N1)pdm09. T-cell responses primarily target internal viral proteins, 
but it has been proposed that CD4 HA epitopes may be the most important for antibody 
generation [16, 17]. Stimulation with rHA revealed responses similar to live-virus 
stimulation, but responses were generally lower with slightly different kinetics 
(Supplementary Figure 3).
B-Cell Responses
Ag-specific plasmablasts (ASCs) derived from the memory B-cell pool peak in peripheral 
blood 7 days after vaccination [18, 19]. IgG- and IgM-producing plasmablasts were assessed 
using 0 days and 7 days PBMCs (Figure 3). Responses were variable, but most individuals 
responded positively to each vaccine component, with greater responses in IgG+ ASCs. 
Consistent with 0 days HI titers (Table 2), preexisting A(H1N1)pdm09- and A/Perth/16-
specific ASCs were detected for IgG and IgM. Fold-rise (GMP ratio) in Ag-specific 
plasmablasts was significant in all parameters, with highest fold-rise in A(H1N1)pdm09-
specific ASCs (IgG and IgM producing), consistent with the highest GMT ratio in HI titers 
(28 days to 0 days; Figure 1).
Vaccination-induced memory B-cell frequency was assessed using PBMCs collected at 0 
and 28 days (Figure 3). Comparable levels of IgG- and IgM-producing memory B cells 
specific to all vaccine components were induced by vaccination. While memory B cells were 
induced to all vaccine components, the greatest induction (GMP ratio for 28 days to 0 days) 
was detected in IgM-producing A(H1N1)pdm09-specific memory B cells (Figure 3).
Effect of Prior Vaccination on Immune Responses
Thirty-eight percent of children in this study received live-attenuated vaccine (LAIV; 10%; 
Table 1) or unadjuvanted TIV (28%; Table 1) during the previous influenza season, and 32% 
received monovalent A(H1N1)pdm09 vaccine (Table 1); 47.4% of children receiving 2009–
2010 seasonal vaccine also received A(H1N1)pdm09 vaccine. Children vaccinated with 
2009–2010 seasonal vaccine maintained higher HI titers prior to vaccination in 2010 (Table 
2). Prior vaccinees did not have higher HI titers to the serologically distinct A(H1N1)pdm09 
strain but had higher preexisting HI titers to the 2010–2011 A(H3N2) strain, A/Perth/16 (P 
≤ .001; Figure 4). Subjects vaccinated with monovalent A(H1N1)pdm09 vaccine exhibited 
HI titers to A(H1N1)pdm09 similar to those exhibited by unvaccinated individuals (Figure 
4). Of note, subjects receiving 2009–2010 seasonal vaccine elicited slightly lower HI titers 
to B/Bris/60 upon vaccination with the same strain during the 2010–2011 season (P ≤ .05; 
Figure 4), although 84.2% still reached HI titers of ≥80 (Table 2).
Interestingly, children receiving 2009–2010 seasonal influenza vaccine exhibited higher 
frequencies of preexisting IFN-γ–secreting CD4+CD69+ cells (P ≤ .05) after stimulation 
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with A(H1N1)pdm09, while the increase in the frequency of TNF-α–secreting CD8+CD69+ 
cells (P = .07) did not reach significance (Figure 5). These responses further increased upon 
receipt of 2010–2011 TIV, although only TNF-α–secreting CD8+CD69+ cells reached 
significance as compared to previously unvaccinated subjects (P ≤ .05). Frequencies of TNF-
α–secreting CD4+CD69+ and IFN-γ–secreting CD8+CD69+ cells showed no differences 
between previously vaccinated and unvaccinated individuals (data not shown). Prior seasonal 
vaccinees (2009–2010) also developed better A/Perth/16-specific TNF-α–secreting 
CD8+CD69+ responses after vaccination with 2010–2011 TIV (P ≤ .05). Subjects receiving 
monovalent A(H1N1)pdm09 vaccine did not exhibit similarly high T-cell responses.
DISCUSSION
Influenza epidemics disproportionately affect children. Nevertheless, challenges associated 
with performing clinical trials in children have limited our understanding of immunity to 
influenza virus in this at-risk population. This study constitutes one of the most 
comprehensive assessments of immunity to seasonal influenza vaccination in children. Our 
results demonstrate the broader influence of annual vaccination, which affects more than a 
single influenza season, and provide insight for future protection studies and vaccine 
development for children.
Recent studies suggest that children may require HI titers greater than the traditional titer of 
40—possibly >100—to achieve a 50% reduction in clinical influenza [15]. Children in our 
study mounted significant serological and cell-mediated responses after immunization with 
2010–2011 TIV. While high HI titers are important for effective protection, sustaining 
prolonged, elevated levels is essential. The majority of children demonstrated HI titers of 
≥160, maintaining titers near or greater than 100 for >7 months (Figure 1 and Table 2). 
2010–2011 TIV also generated significant IFN-γ–producing CD4+CD69+ cells responsive 
to A(H1N1)pdm09 and A/Perth/16 (Figure 2). Studies suggest that IFN-γ–producing cells 
correlate well with protection in young children [20].
Children exhibited moderately elevated HI titers prior to 2010–2011 vaccination. Elevated 
A(H3N2)- and B-specific titers are consistent with prior vaccination (discussed below). 
However, A(H1N1)pdm09 is serologically distinct from A/Bris/59, the prior A(H1N1) 
component, yet 68% had A(H1N1)pdm09 HI titers of ≥40 prior to vaccination (Table 2). As 
neither seasonal nor monovalent A(H1N1)pdm09 vaccinees had significant serological 
differences from unvaccinated individuals, this likely reflects prior infection (Figure 4). 
Studies examining longitudinal immunogenicity demonstrated rapid decline in HI titers 
invoked by A(H1N1)pdm09 vaccine [21, 22]. In contrast to monovalent A(H1N1)pdm09 
vaccine, 67.3% of children vaccinated with 2010–2011 TIV maintained A(H1N1)pdm09 HI 
titers of ≥160 for >7 months (Table 2). Differences in longevity could be explained as a 
booster effect, with children maintaining higher HI titers over a longer period because of a 
secondary response stimulated by primary exposure to monovalent A(H1N1)pdm09 vaccine 
and/or natural infection. Alternatively, enhanced T-cell responses induced by 2010–2011 
TIV may have aided in the longevity of the response (Figure 2 and Supplementary Figure 3).
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Plasmablast responses at 7 days are indicative of an accelerated secondary response [18, 19]. 
Although subjects were relatively young, their robust IgG- and IgM-producing ASC 
formation at 7 days suggest development from an already established memory B-cell pool, 
readily differentiating to plasmablasts in response to strains in the new seasonal vaccine. 
IgG-producing plasmablasts were predominant, but significant IgM-producing plasmablasts 
were produced, albeit at reduced levels to IgG. Additionally, induction of long-lived IgM 
memory B cells was comparable to IgG counterparts (Figure 3). Although studies show that 
IgM memory B cells participate in secondary responses to bacterial or inert Ag primarily by 
entering germinal centers, rather than by directly secreting antibodies [23–27], their role in 
repeated influenza vaccine responses remains unknown. Considering that secondary 
antibody responses are typically dominated by highly specific IgG and little, if any, IgM, our 
current findings may indicate a continual maturation of the B-cell compartment in this age 
group. Studies examining plasmablast responses in adults who received A(H1N1)pdm09 
vaccine showed a predominance of IgG-over IgM-producing plasmablasts in adults [18].
Influenza vaccination of children resulted in broader immunity than to strains included in the 
vaccine and influenced responses the following year. Children receiving 2009–2010 seasonal 
vaccine maintained high HI titers into 2010 and stimulated responses to strains not present in 
the vaccine (Figure 4 and Table 2). Children vaccinated with A/Bris/10, the 2009–2010 
A(H3N2) vaccine component, demonstrated elevated A/Perth/16 HI titers, the future (2010–
2011) A(H3N2) component, prior to vaccination in 2010 (Table 2). Conversely, vaccination 
with 2010–2011 TIV boosted HI titers to all 2009–2010 components. B/Bris/60, an 
influenza B Victoria lineage strain, also boosted HI titers to B/Flor/4, a Yamagata lineage 
strain from the 2008–2009 season (Figure 1). Studies in adults vaccinated during the 2006–
2007 influenza season demonstrated the induction of cross-reactive antibodies to drifted 
influenza virus strains that emerged the following year [28]. Those studies further showed 
that adults were less able to induce cross-reactive antibodies with increasing age.
Relatively few studies have examined cross-protection against drifted seasonal influenza 
virus in children, which is afforded by TIV. Vesikari et al [29, 30] addressed cross-reactive 
HI titers in children vaccinated with MF59-adjuvanted versus unadjuvanted influenza 
vaccines. Children in those studies receiving 2 doses of unadjuvanted vaccine exhibited 
variable cross-reactivity, with moderate cross-reactivity to drifted A(H3N2) strains and little 
to none with B strains (also mismatches between Yamagata and Victoria lineages). Our 
study demonstrated much higher cross-reactivity to drifted strains, especially the B strain; 
however, our study was performed in older children, who respond better to vaccination. 
Vesikari et al examined children ages 6–72 months [30] and 6–35 months [29].
Influenza virus continuously evolves through antigenic drift, the gradual accumulation of 
point mutations allowing it to reinfect previously protected hosts [2]. However, this gradual 
evolution retains enough conserved epitopes with the previous strain to provide at least 
partial protection. Recent studies on human antibody responses against A(H3N2) strains 
showed substantially increased HI titers against historic strains, depending on antigenic 
distance from the infecting virus, an effect termed “back-boost” [5]. Boosting of related 
strains observed in our study, while consistent with cross-reactive epitopes, may also be 
explained by the back-boost effect.
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Preexisting T-cell responses to A(H1N1)pdm09, presumably derived from cross-reactive 
epitopes from prior seasonal infection or vaccination, have been demonstrated in humans 
[16,31]. Children in our study who received 2009–2010 seasonal influenza vaccine exhibited 
higher frequencies of preexisting T cells to A(H1N1)pdm09 (Figure 5). Similarly, adults 
vaccinated with 2007–2008 seasonal influenza exhibited enhanced IFN-γ–producing cells to 
A(H1N1)pdm09 according to ELISPOT analysis [32]. Although subjects receiving 
monovalent A(H1N1)pdm09 vaccine exhibited T-cell responses to A(H1N1)pdm09, the 
level was similar to that in unvaccinated individuals (Figure 5). In a similar study, children 
vaccinated with ASO3-adjuvanted monovalent A(H1N1)pdm09 vaccine demonstrated 
higher frequencies of IFN-γ–producing cells according to ELISPOT, which persisted into 
the 2010–2011 season; those vaccinated with unadjuvanted whole-virion vaccine 
demonstrated a much lower level of IFN-γ–producing cells [33]. Similar to our results, 
vaccination with 2010–2011 seasonal vaccine further expanded T-cell responses to levels 
higher than those in subjects who were not previously vaccinated (Figure 5). While the 
studies performed in adults vaccinated with 2007–2008 seasonal vaccine were performed 
prior to A(H1N1)pdm09 circulation [32], our results cannot definitively attribute preexisting 
CD4+ and CD8+ cellular responses solely to prior 2009–2010 vaccination; our results 
suggest prior pandemic infection and therefore the possibility of a prime-boost effect from 
seasonal vaccine followed by pandemic infection (Table 2, Figure 1). However, only subjects 
receiving prior seasonal vaccination exhibited these enhanced T-cell responses to pandemic 
virus, demonstrating the major role of prior seasonal vaccination in this effect.
The effect of prior vaccination was analyzed by grouping all previously vaccinated subjects 
regardless of receiving TIV or LAIV. Vaccine type exerts differential effects on immune 
responses. LAIV stimulates higher T-cell responses in young children, compared with TIV 
[34, 35]. The 2 types of vaccines also influence responses in different lymphoid tissues and 
stimulate different antibody repertoires, as well as promote differential T- and B-cell 
phenotypes [36, 37]. Although the type of vaccine received the previous year potentially 
influenced responses in the subsequent influenza season, sample size precluded further 
subdividing this group to examine such interactions.
Our study has several limitations. The young age of subjects limited blood sample volumes, 
restricting the number of analyses that could be performed, especially T- and B-cell 
analyses. PBMCs were collected on different days after vaccination, to accommodate critical 
time points for plasmablasts, memory B cells, and T cells. While subdividing our cohort into 
different sample days allowed a more comprehensive evaluation, it reduced statistical power. 
Our cohort also had limited racial diversity and was slightly skewed toward males (Table 1).
Children in this study exhibited serological and cell-mediated immunity broader than 
components present in that year’s vaccine. Vaccination boosted serological responses to 
strains experienced not only in the past, likely through cross-reactivity and/or the back-boost 
effect, but also against strains that would circulate in the subsequent season. Although 
vaccination of subjects who had not received the previous year’s seasonal vaccine induced 
HI titers comparable to subjects who received prior vaccination, subjects who were 
previously vaccinated were likely afforded some level of preexisting protection prior to 
receipt of the vaccine in the following year. In contrast to serological responses, children 
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receiving prior seasonal vaccination appeared to have enhanced T-cell responses upon 
vaccination in the subsequent year. The increased breadth of immunity to future strains is 
likely important for children who do not consistently receive annual influenza vaccination 
and in years when vaccine delivery is delayed or the influenza season gets off to an early 
start. Prior seasonal vaccination also stimulated IFN-γ– and TNF-α–producing T cells 
responsive to serologically distinct A(H1N1)pdm09. Whether these cross-reactive cells are 
the result of vaccination with prior seasonal vaccine alone or due to a prime-boost effect 
from vaccination followed by infection is uncertain. Nevertheless, the ability of seasonal 
vaccines to induce cross-reactive HI titers and T cells against future strains stresses the 
importance of yearly vaccination and warrants further investigation.
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Figure 1. 
Hemagglutination-inhibition (HI) titers of children vaccinated with 2010–2011 trivalent 
inactivated influenza vaccine (TIV). HI titers to influenza virus strains included in the 2010–
2011 TIV (2009 pandemic influenza A[H1N1] virus [A{H1N1}pdm09], A/Perth/16, and B/
Bris/60), the 2009–2010 TIV (A/Bris/59, A/Bris10, and B/Bris/60), and the 2008–2009 TIV 
(B/Flor/4) were assessed at 0 days, 28 days, and 7 months after vaccination. Geometric 
mean titer (GMT) ratios (fold rise) were calculated using repeated measures linear mixed 
models for 28 days vs 0 days, 7 months vs 0 days, and 7 months vs 28 days. A GMT ratio of 
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>1 (line) is indicative of a higher postvaccination response. Error bars represent 1 standard 
error. *P ≤ .05, **P ≤ .01, and †P ≤ .001.
Reber et al. Page 13
J Infect Dis. Author manuscript; available in PMC 2017 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
T-cell responses to live-virus stimulation. Cytokine production by activated (CD69+) T cells 
induced by live-virus stimulation were assessed prior to (0 days) and either 7, 14, or 28 days 
after vaccination with 2010–2011 trivalent inactivated influenza vaccine. Geometric mean 
percentage (GMP) ratios vs 0 days were calculated for each time point after vaccination, 
using repeated measures linear mixed models. A GMP ratio of >1 (line) is indicative of a 
higher postvaccination response. T-cell activation is expressed as CD4+CD69+ or 
CD8+CD69+ cells in total CD4+ or CD8+ T cells. Cytokine-producing cells are expressed as 
percentages of total CD4+CD69+ or CD8+CD69+ T cells. Error bars represent 1 standard 
error. *P ≤ .05 and **P ≤ .01.
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Figure 3. 
Plasmablast and memory B-cell responses. Immunoglobulin M (IgM)– and immunoglobulin 
G (IgG)–producing plasmablasts and memory B cells specific for 2009 pandemic influenza 
A(H1N1) virus (A[H1N1]pdm09) (H1), A/Victoria/2009 (H3), and B/Bris/60 (B) were 
assessed in children before and after vaccination with 2010–2011 trivalent inactivated 
influenza vaccine. Geometric mean ratio and geometric mean percentage (GMP) ratio vs 0 
days were calculated against the postvaccination time points, using repeated measures linear 
mixed models. A ratio of >1 (line) is indicative of a higher postvaccination response. Error 
bars represent 1 standard error. *P ≤ .05, **P ≤ .01, and ***P ≤ .001.
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Figure 4. 
The effect of prior seasonal vaccination on hemagglutination-inhibition (HI) responses. 
Induction of HI titers by 2010–2011 trivalent inactivated influenza virus (TIV) was assessed 
in subjects who received prior influenza vaccination during the 2009–2010 influenza season 
(V) and those who did not (UV). Vaccination with prior seasonal influenza vaccine and 
monovalent 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) vaccine were 
assessed separately. HI titers to influenza virus strains included in the 2010–2011 TIV 
(A[H1N1]pdm09, A/Perth/16, and B/Bris/60), the 2009–2010 TIV (A/Bris/59, A/Bris10, 
and B/Bris/60), and the 2008–2009 TIV (B/Flor/4) were assessed at 0 days, 28 days, and 1 
year after vaccination. Differences between previously vaccinated and unvaccinated subjects 
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were determined using unpaired t tests. Error bars represent 1 standard error. Significance is 
indicated by *P ≤ .05 and ***P ≤ .001.
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Figure 5. 
Effect of prior vaccination on T-cell responses. The percentage of interferon γ–secreting 
CD4+CD69+ and TNF-α–secreting CD8+CD69+ cells responding to stimulation with live 
2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) or A/Perth/16 virus were 
determined in subjects vaccinated (V) with seasonal influenza vaccine or the monovalent 
A(H1N1)pdm09 vaccine during the 2009–2010 influenza season as compared to subjects 
who were not vaccinated (UV) with these respective vaccines. Differences between 
previously vaccinated and unvaccinated subjects were determined using unpaired t tests. 
Error bars represent 1 standard error. *P ≤ .05.
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Table 1
Subject Characteristics, by Postvaccination Time of Peripheral Blood Mononuclear Cell Collection After 
Vaccination
Group
Overall
(n = 50)
7 d
(n = 16)
14d
(n = 17)
28 d
(n = 17)
Age, y
 Range 9–14 9–14 10–14 9–14
 Average 11.8 12.0 11.8 11.5
Sex
 Male 68.0 68.8 58.8 76.5
 Female 32.0 31.2 41.2 23.5
Race
 White 96.0 87.5 100.0 100.0
 Other 4.0 12.5 0.0 0.0
Prior vaccine receipt
 2009–2010 TIV 28.0 25.0 35.3 23.5
 2009–2010 LAIV 10.0 6.3 17.6 5.9
 A(H1N1)pdm09 monovalent 32.0 18.8 23.5 52.9
Data are percentage of subjects, unless otherwise indicated.
Abbreviations: A(H1N1)pdm09, 2009 pandemic influenza A(H1N1); LAIV, live-attenuated vaccine; TIV, trivalent inactivated influenza vaccine.
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